#1 Clinical Trials Search in Europe

ORX750

ORX750 is an investigational drug currently being studied in clinical trials for people with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). These rare conditions cause excessive daytime sleepiness that can significantly impact daily activities. ORX750 is designed to mimic the action of orexin, a protein in the brain that helps people stay awake during the day. The current clinical trials aim to evaluate the safety, tolerability, and effectiveness of ORX750 in reducing symptoms associated with these sleep disorders. Let’s explore what these trials reveal about this promising treatment option.

Table of Contents

What is ORX750?

ORX750 is an investigational medication being studied for the treatment of sleep disorders characterized by excessive daytime sleepiness. It is administered as an oral capsule and is currently in Phase 2 clinical trials[1]. The drug is designed to mimic the action of orexin, a natural protein in the brain that plays a critical role in regulating wakefulness and sleep cycles[2].

Conditions Treated with ORX750

ORX750 is being studied for three specific sleep disorders[1][2]:

  • Narcolepsy Type 1 (NT1) – A condition characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle strength triggered by strong emotions like laughter or surprise). People with NT1 may collapse or lose control of their muscles for short periods when experiencing strong emotions. They often have disrupted nighttime sleep as well.
  • Narcolepsy Type 2 (NT2) – Similar to NT1 in that it causes excessive daytime sleepiness, but people with NT2 do not experience cataplexy. They still struggle to stay alert and attentive during daily activities.
  • Idiopathic Hypersomnia (IH) – A condition where people feel excessively tired during the day despite sleeping normal or extended hours at night. People with IH may sleep for long periods, take extended naps, and find it particularly difficult to wake up. The term “idiopathic” means the cause is unknown.

All three conditions can significantly impact a person’s ability to function at school, work, while driving, or during other daily activities due to the overwhelming sleepiness they cause[2].

How ORX750 Works

ORX750 is designed to mimic the action of orexin, a protein in the brain that helps coordinate the wakefulness system[2]. Orexin is crucial for maintaining proper sleep-wake cycles.

In people with narcolepsy type 1, the brain cells that produce orexin are damaged or destroyed, leading to a deficiency of this important protein. By mimicking orexin’s action, ORX750 aims to restore the normal function of the wakefulness system in the brain, helping patients feel more alert during the day[2].

Clinical Studies on ORX750

ORX750 is currently being evaluated in clinical trials to determine its safety and effectiveness. Two significant studies are underway:

  • CRYSTAL-1 Study – This is a Phase 2a, randomized, double-blind, placebo-controlled study (NCT06752668) designed to evaluate the safety, tolerability, pharmacokinetics (how the drug moves through the body), and pharmacodynamics (how the drug affects the body) of ORX750 in patients with narcolepsy and idiopathic hypersomnia[2]. In this study, participants are randomly assigned to receive either ORX750 or a placebo (a pill that looks identical but contains no active medication).
  • Long-term Extension Study – This is an open-label, long-term extension study (NCT07096674) designed to provide information about the long-term safety, tolerability, and effectiveness of ORX750[1]. Participants who complete the parent study (CRYSTAL-1) may be eligible to continue receiving ORX750 in this extension study. Unlike the parent study, all participants in the extension study receive ORX750 (no placebo group).

Safety Monitoring During Clinical Trials

The safety of participants is a primary focus in these clinical trials. Several measures are being used to monitor safety[1][2]:

  1. Treatment Emergent Adverse Events (TEAEs) – Researchers track any side effects that occur during treatment, including serious adverse events that might require medical attention.
  2. Laboratory Tests – Blood and other laboratory tests are conducted regularly to check for any abnormal changes from baseline (before starting treatment).
  3. Vital Signs – Measurements such as blood pressure, heart rate, temperature, and respiratory rate are monitored for any concerning changes.
  4. Electrocardiograms (ECGs) – These tests monitor heart activity to detect any abnormal changes in heart rhythm or function.
  5. Columbia-Suicide Severity Rating Scale (C-SSRS) – This assessment tool monitors for any suicidal thoughts or behaviors that might emerge during treatment.

How Effectiveness is Measured

The clinical trials are evaluating how well ORX750 works using several standardized measures[1][2]:

  • Maintenance of Wakefulness Test (MWT) – This test measures a person’s ability to stay awake in a quiet, dimly lit environment. The mean sleep latency (average time it takes to fall asleep) is calculated across multiple test trials. An increase in mean sleep latency would indicate improvement in the ability to stay awake.
  • Epworth Sleepiness Scale (ESS) – This is a questionnaire that asks patients to rate their likelihood of falling asleep in various situations. A decrease in the ESS score would indicate improvement in daytime sleepiness.

In addition, researchers are measuring how ORX750 is processed by the body by looking at factors such as:

  • Maximum Observed Plasma Concentration (Cmax) – The highest level of drug in the bloodstream after dosing.
  • Time of Maximum Concentration (Tmax) – How long it takes to reach the maximum drug concentration in the blood.
  • Area Under the Curve (AUC) – A measure of the total exposure to the drug over time.
  • Steady State Measurements – Assessments of drug levels after regular dosing when concentrations have stabilized in the body.

These pharmacokinetic measurements help researchers understand how the drug moves through the body and how long it remains active, which is important for determining optimal dosing schedules[1][2].

Aspect Details
Drug Name ORX750
Mechanism of Action Designed to mimic orexin, a brain protein that helps maintain wakefulness
Conditions Studied Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), Idiopathic Hypersomnia (IH)
Primary Outcomes Measured – Treatment Emergent Adverse Events (TEAEs)
– Changes in laboratory tests
– Changes in vital signs
– Changes in electrocardiograms (ECGs)
– Suicidal ideation or behavior (C-SSRS)
Efficacy Measures – Maintenance of Wakefulness Test (MWT) mean sleep latency
– Epworth Sleepiness Scale (ESS) scores
Current Trials – Phase 2a randomized, double-blind, placebo-controlled study (CRYSTAL-1)
– Phase 2 long-term extension (LTE) open-label study
Administration Oral capsule

FAQ

  • What conditions is ORX750 being tested for in clinical trials? ORX750 is being tested for three sleep-related conditions: Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH). All these conditions cause excessive daytime sleepiness, though they have some differences in symptoms. NT1 includes cataplexy (sudden loss of muscle strength often triggered by emotions), NT2 causes sleepiness without cataplexy, and IH causes prolonged sleep periods with difficulty waking up.
  • How does ORX750 work in the body? ORX750 is designed to mimic the action of orexin, which is a protein in the brain that helps coordinate the system responsible for keeping people awake during the day. In conditions like narcolepsy, the orexin system may not function properly. ORX750 aims to substitute for this missing or malfunctioning orexin to help patients maintain better wakefulness and reduce excessive sleepiness.
  • What are the main goals of the clinical trials studying ORX750? The main goals of the ORX750 clinical trials are to: 1) Evaluate the safety and tolerability of the drug in patients with NT1, NT2, and IH; 2) Study how the drug works in the body (pharmacokinetics); 3) Measure if ORX750 helps reduce excessive daytime sleepiness using tests like the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale; and 4) Monitor for any adverse effects through various assessments including laboratory tests, vital signs, and electrocardiograms.
  • What types of clinical trials are being conducted with ORX750? There are currently two types of clinical trials mentioned for ORX750: 1) A Phase 2a randomized, double-blind, placebo-controlled study (CRYSTAL-1) that compares ORX750 to a placebo to determine safety, tolerability, and effects; and 2) A Phase 2 long-term extension (LTE) open-label study that allows participants who completed the initial trial to continue taking ORX750 to gather data on long-term safety and efficacy.
  • How is the effectiveness of ORX750 being measured in these trials? The effectiveness of ORX750 is being measured using specific tests and scales: 1) The Maintenance of Wakefulness Test (MWT), which measures how long participants can stay awake in a quiet, dimly lit environment; 2) The Epworth Sleepiness Scale (ESS), a questionnaire that assesses a person's general level of daytime sleepiness in various situations. Both tests compare baseline measurements (before treatment) to measurements taken during and after treatment to determine if ORX750 helps participants stay more alert and less sleepy.

Ongoing Clinical Trials on ORX750

  • Long-term Safety Study of ORX750 for Patients with Narcolepsy and Idiopathic Hypersomnia Who Completed a Previous ORX750 Trial

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study on the Safety and Effects of ORX750 for Patients with Narcolepsy and Idiopathic Hypersomnia

    Recruiting

    1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

Glossary

  • Narcolepsy Type 1 (NT1): A sleep disorder characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle strength triggered by strong emotions). People with NT1 often experience disrupted nighttime sleep.
  • Narcolepsy Type 2 (NT2): A sleep disorder similar to NT1 with excessive daytime sleepiness, but without cataplexy. Patients experience an overwhelming urge to sleep during the day despite adequate nighttime sleep.
  • Idiopathic Hypersomnia (IH): A sleep disorder characterized by excessive daytime sleepiness despite long periods of nighttime sleep. People with IH often have difficulty waking up, may take long naps, and experience sleep inertia (prolonged grogginess after waking).
  • Cataplexy: A sudden, temporary loss of muscle strength or control typically triggered by strong emotions like laughter, surprise, or anger. It's a characteristic symptom of Narcolepsy Type 1.
  • Excessive Daytime Sleepiness (EDS): An overwhelming need to sleep during daytime hours, making it difficult to stay alert for daily activities like school, work, or driving.
  • Orexin: A protein in the brain that helps regulate wakefulness, appetite, and arousal. In narcolepsy type 1, there is often a deficiency of orexin-producing neurons.
  • Maintenance of Wakefulness Test (MWT): A standardized test that measures how long a person can stay awake in a quiet, dimly lit environment. It's used to objectively measure daytime sleepiness and the ability to stay awake.
  • Epworth Sleepiness Scale (ESS): A questionnaire used to measure a person's general level of daytime sleepiness. It asks about the likelihood of falling asleep in various situations, with higher scores indicating greater sleepiness.
  • Phase 2 Clinical Trial: A stage of clinical research that studies a drug's effectiveness for a specific medical condition and continues to evaluate its safety. Phase 2 trials involve more participants than Phase 1 trials.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo. This helps prevent bias in evaluating results.
  • Placebo-controlled: A study where some participants receive an inactive substance (placebo) instead of the study drug, allowing researchers to compare the effects of the real treatment against no treatment.
  • Open-label: A type of clinical trial where both researchers and participants know which treatment is being administered. The long-term extension study of ORX750 is open-label.
  • Long-term Extension (LTE) Study: A continuation study that allows participants who completed the initial clinical trial to continue receiving the study drug, usually to gather data on long-term safety and effectiveness.
  • Treatment Emergent Adverse Events (TEAEs): Unwanted medical occurrences that begin or worsen after starting a treatment in a clinical trial. Monitoring these events helps evaluate a drug's safety.
  • Columbia-Suicide Severity Rating Scale (C-SSRS): A questionnaire used to assess suicidal ideation and behavior in clinical trials to monitor participant safety.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated. Measurements include parameters like Cmax (maximum concentration) and AUC (area under the curve).
  • Cmax: Maximum Observed Plasma Concentration – the highest concentration of a drug in the blood after administration.
  • Tmax: Time of Maximum Concentration – the time it takes for a drug to reach its highest concentration in the blood.
  • AUC (Area Under the Curve): A measurement of the total exposure to a drug over time, used to determine how much drug reaches the bloodstream.

References